Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

WSJ: Teva close to CEO choice, with acting CEO and ex-Actavis chief still up for the job

Teva Pharmaceutical Industries is said to be close to choosing Israeli executive Erez Vigodman to take its empty CEO chair, but as the Wall Street Journal reports, some other candidates are still in the running.

Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire

Gilead Sciences just rolled out its much-anticipated hepatitis C treatment Sovaldi (sofosbuvir) last month. Now, the company's commercial chief is saying sayonara. EVP Kevin Young will retire Feb. 4, leaving his team to soldier on alone with the Sovaldi launch.

Rebel Teva shareholder throws his support to presumptive CEO Vigodman

Balky Teva shareholder Benny Landa has fallen in line behind the company's apparent choice for CEO, Erez Vigodman. As the Financial Times reports, Landa is once again circulating an email to fellow major shareholders--but this time to support the company's board rather than attack it.

Mylan has hired away a new India president from Biocon, its partner there

Mylan turned to India's Biocon last year for expertise on making biosimilars. This year, the generic drug maker is turning to Biocon for someone to run its extensive operations in that country.

Genetics startup Agilis names industry vet Zorich CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Cue more drama in Teva's boardroom as its CEO announcement nears

Teva Pharmaceutical Industries appears to be on the verge of naming a replacement for former helmsman Jeremy Levin, but the  Financial Times  reports that shareholders are also pressing for a boardroom change-up that could end with a new occupant for the chairman's seat.

In a swift split, Pfizer's Schulman leaves before starting new job as vaccines head

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Pfizer head-scratcher: Schulman was toasted on Thursday, toast by Tuesday

As recently as last Thursday, Pfizer's Amy Schulman was fully expecting to move into a new and better job at Pfizer on Jan. 1. By Tuesday, she was out of a job altogether. So writes Fortune' s Patricia Sellers, who lunched with Schulman last week in New York.

Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit

In July, Amy Schulman looked to be one of the most powerful women in Big Pharma. As part of CEO Ian Read's plan to split Pfizer's internal operations into three distinct units, he tapped Schulman to lead the company's vaccines, oncology and consumer healthcare business. Now, Schulman is out.

Ex-Merck R&D chief Kim to teach at Stanford med school

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...